SDC1 and plasma cell myeloma: In the treatment of multiple myeloma, TAT associating the alpha particle emitter, astatine-211, and a full size anti-CD138 antibody appears to be a beneficial combination that provides complete responses in 65% of cases without long-term radiotoxicity.